Top-line success for AstraZeneca's Brilinta
This article was originally published in Scrip
AstraZeneca's investigational oral antiplatelet therapy ticagrelor (Brilinta) has met the primary endpoint in a Phase III study comparing it with clopidogrel (Bristol-Myers Squibb/Sanofi-Aventis's (Plavix), the company has announced. The study was designed to see whether ticagrelor is better than clopidogrel in reducing the risk of thrombotic events in acute coronary syndromes (ACS) patients.
You may also be interested in...
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.